Chou P, Lee Y, Chang Y, Lin P, Wang L
Clin Psychopharmacol Neurosci. 2023; 21(3):488-498.
PMID: 37424417
PMC: 10335907.
DOI: 10.9758/cpn.22.1000.
Ghadery C, Kalia L, Connolly B
J Neurol. 2022; 269(11):5812-5830.
PMID: 35904592
DOI: 10.1007/s00415-022-11299-1.
Yeh J, Chiu N, Chang Y, Lin P, Lee Y
Clin Psychopharmacol Neurosci. 2020; 18(2):331-336.
PMID: 32329314
PMC: 7242099.
DOI: 10.9758/cpn.2020.18.2.331.
Hsieh M, Lin P, Tsai C, Chang C, Lee Y
BMC Pharmacol Toxicol. 2017; 18(1):41.
PMID: 28583166
PMC: 5460531.
DOI: 10.1186/s40360-017-0148-3.
Fleischhacker W, Hofer A, Jagsch C, Pirker W, Psota G, Rittmannsberger H
Neuropsychiatr. 2016; 30(3):123-130.
PMID: 27580887
DOI: 10.1007/s40211-016-0189-7.
Clinical significance of pharmacogenomic studies in tardive dyskinesia associated with patients with psychiatric disorders.
Chang F, Fung V
Pharmgenomics Pers Med. 2014; 7:317-28.
PMID: 25378945
PMC: 4207069.
DOI: 10.2147/PGPM.S52806.
Oromandibular dystonia in yemeni patients with khat chewing: a response to botulinum toxin treatment.
Shehata H, El-Tamawy M, Mohieldin N, Edrees M, Bohlega S
Neurol Int. 2014; 6(2):5385.
PMID: 24987506
PMC: 4077212.
DOI: 10.4081/ni.2014.5385.
Maladaptive plasticity in levodopa-induced dyskinesias and tardive dyskinesias: old and new insights on the effects of dopamine receptor pharmacology.
Cerasa A, Fasano A, Morgante F, Koch G, Quattrone A
Front Neurol. 2014; 5:49.
PMID: 24782822
PMC: 3988357.
DOI: 10.3389/fneur.2014.00049.
Benefical effects of sigma-1 agonist fluvoxamine for tardive dyskinesia and tardive akathisia in patients with schizophrenia: report of three cases.
Albayrak Y, Hashimoto K
Psychiatry Investig. 2014; 10(4):417-20.
PMID: 24474992
PMC: 3902161.
DOI: 10.4306/pi.2013.10.4.417.
An update on tardive dyskinesia: from phenomenology to treatment.
Waln O, Jankovic J
Tremor Other Hyperkinet Mov (N Y). 2013; 3.
PMID: 23858394
PMC: 3709416.
DOI: 10.7916/D88P5Z71.
Beneficial effects of the sigma-1 agonist fluvoxamine for tardive dyskinesia in patients with postpsychotic depressive disorder of schizophrenia: report of 5 cases.
Albayrak Y, Hashimoto K
Prim Care Companion CNS Disord. 2013; 14(6).
PMID: 23585988
PMC: 3622527.
DOI: 10.4088/PCC.12br01401.
Drug-induced parkinsonism.
Shin H, Chung S
J Clin Neurol. 2012; 8(1):15-21.
PMID: 22523509
PMC: 3325428.
DOI: 10.3988/jcn.2012.8.1.15.
Twelve cases of drug-induced blepharospasm improved within 2 months of psychotropic cessation.
Emoto Y, Emoto H, Oishi E, Hikita S, Wakakura M
Drug Healthc Patient Saf. 2011; 3:9-14.
PMID: 21753898
PMC: 3132861.
DOI: 10.2147/DHPS.S20691.
Eating dysfunction associated with oromandibular dystonia: clinical characteristics and treatment considerations.
Papapetropoulos S, Singer C
Head Face Med. 2006; 2:47.
PMID: 17156419
PMC: 1702536.
DOI: 10.1186/1746-160X-2-47.
Tardive Dystonia.
Skidmore F, Reich S
Curr Treat Options Neurol. 2005; 7(3):231-236.
PMID: 15814076
DOI: 10.1007/s11940-005-0016-0.
Tardive Dyskinesia.
Tarsy
Curr Treat Options Neurol. 2000; 2(3):205-214.
PMID: 11096748
DOI: 10.1007/s11940-000-0003-4.
Tardive and idiopathic oromandibular dystonia: a clinical comparison.
Tan E, Jankovic J
J Neurol Neurosurg Psychiatry. 2000; 68(2):186-90.
PMID: 10644785
PMC: 1736782.
DOI: 10.1136/jnnp.68.2.186.
Pharmacological options for the management of dyskinesias.
Shale H, Tanner C
Drugs. 1996; 52(6):849-60.
PMID: 8957155
DOI: 10.2165/00003495-199652060-00006.
